公开(公告)号：EP1948800A4

公开(公告)日：2010-07-21

申请号：EP06790408

申请日：2006-10-20

申请人： MELBOURNE HEALTH ,  AUSTIN HEALTH

发明人： BARTHOLOMEUSZ ANGELINE INGRID ,  LOCARNINI STEPHEN ,  AYRES ANNA ,  LITTLEJOHN MARGARET ,  ANGUS PETER WILLIAM

IPC分类号： C12N15/51 ,  A61K35/76 ,  C12N7/06

CPC分类号： A61K35/76 ,  C12N7/00 ,  C12N2730/10132 ,  C12Q1/18

摘要： The present invention relates generally to viral variants exhibiting reduced sensitivity to agents such as nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.

公开(公告)号：EP0586065B1

公开(公告)日：2010-03-24

申请号：EP93305591.5

申请日：1993-07-16

申请人： Advanced Life Science Institute, Inc ,  Tokyo Metropolitan Organization for Medical Research ,  Kiyosawa, Kendo ,  SYSMEX CORPORATION

发明人： Hasegawa, Akira ,  Maki, Noboru ,  Yagi, Shintaro ,  Kashiwakuma, Tomiko ,  Yamaguchi, Kenjiro ,  Ikeguchi, Naoko ,  Kobayashi, Tomoko ,  Senoo, Chiaki

IPC分类号： C12N15/51 ,  C07K14/00 ,  G01N33/576 ,  A61K39/29

CPC分类号： C07K14/005 ,  C12N2770/24222

公开(公告)号：EP0662133B1

公开(公告)日：2009-11-18

申请号：EP93922703.9

申请日：1993-09-17

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

发明人： TSAREV, Sergei, A. ,  EMERSON, Suzanne, U. ,  PURCELL, Robert, H.

IPC分类号： C12N15/51 ,  C12N7/00 ,  C12N15/40 ,  A61K39/29 ,  G01N33/576

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  C07H21/00 ,  C12N7/00 ,  C12N15/1131 ,  C12N2310/3125 ,  C12N2310/314 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/341 ,  C12N2310/345 ,  C12N2310/346 ,  C12N2710/14143 ,  C12N2770/28021 ,  C12N2770/28022 ,  C12N2770/28122 ,  C12N2770/28123 ,  Y10S977/802 ,  C12N2310/3521

公开(公告)号：EP1824978A4

公开(公告)日：2008-09-10

申请号：EP05808052

申请日：2005-11-18

申请人： VALORISATION HSJ SOC EN COMMAN

发明人： SOUDEYNS HUGO ,  TROESCH MYRIAM ,  JALBERT EMILIE

IPC分类号： C12N15/51 ,  A61K39/29 ,  A61P31/14 ,  C07K14/18 ,  C07K16/10 ,  C12P21/02 ,  C12Q1/70 ,  G01N33/576

CPC分类号： G01N33/5767 ,  A61K2039/5256 ,  A61K2039/605 ,  A61K2039/625 ,  C07K14/005 ,  C12N2770/24222 ,  C12Q1/707

摘要： The invention provides polypeptides, nucleic acids, antibodies, compositions, vaccines, microarrays and uses thereof for the prevention, treatment of HCV infection. The invention further provides uses of the above-noted products for the detection and diagnosis of HCV infection. The invention further provides corresponding methods and commercial packages relating to such uses. The invention further provides recombinant polypeptides and methods for their production.

公开(公告)号：EP1185665B1

公开(公告)日：2008-09-10

申请号：EP00939534.4

申请日：2000-06-02

申请人： The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services

发明人： BUKH, Jens ,  YANAGI, Masayuki ,  EMERSON, Suzanne, U. ,  PURCELL, Robert, H.

IPC分类号： C12N15/51 ,  C07K14/18 ,  C12Q1/68 ,  C12N7/00

CPC分类号： C07K14/005 ,  C07K2319/00 ,  C12N2770/24222

公开(公告)号：EP1948800A1

公开(公告)日：2008-07-30

申请号：EP06790408.6

申请日：2006-10-20

申请人： Melbourne Health ,  Austin Health

发明人： BARTHOLOMEUSZ, Angeline, Ingrid ,  LOCARNINI, Stephen ,  AYRES, Anna ,  LITTLEJOHN, Margaret ,  ANGUS, Peter, William

IPC分类号： C12N15/51 ,  A61K35/76 ,  C12N7/06

CPC分类号： A61K35/76 ,  C12N7/00 ,  C12N2730/10132 ,  C12Q1/18

摘要： The present invention relates generally to viral variants exhibiting reduced sensitivity to agents such as nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.

公开(公告)号：EP1765990A4

公开(公告)日：2008-07-09

申请号：EP05742151

申请日：2005-05-19

申请人： MELBOURNE HEALTH ,  MURDOCH CHILDRENS RES INST

发明人： LOCARNINI STEPHEN ,  VISVANATHAN KUMAR

IPC分类号： C12N7/00 ,  A61K38/00 ,  A61K38/16 ,  A61K39/00 ,  C07K14/02 ,  C12N15/12 ,  C12N15/51 ,  C12Q1/68 ,  C12Q1/70

CPC分类号： C12Q1/706 ,  A61K38/162 ,  A61K39/00 ,  C07K14/005 ,  C12N2730/10122 ,  C12Q2600/158

公开(公告)号：EP1601327A4

公开(公告)日：2008-04-02

申请号：EP04713363

申请日：2004-02-20

申请人： LORANTIS LTD

发明人： PAGE MARK ,  FRIEDE MARTIN ,  SCHMIDT ANNETTE ELISABETH ,  STOBER DETLEF

IPC分类号： A61K39/00 ,  A61K39/29 ,  C07K14/02 ,  C12N7/04 ,  C12N15/36 ,  A61K38/00 ,  A61K39/12 ,  A61K39/385 ,  C07K14/00 ,  C07K14/005 ,  C12N15/09 ,  C12N15/31 ,  C12N15/33 ,  C12N15/51 ,  C12P21/00

CPC分类号： A61K39/292 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/5258 ,  A61K2039/545 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/55566 ,  A61K2039/55572 ,  C07K14/005 ,  C07K2319/00 ,  C12N7/00 ,  C12N2730/10122 ,  C12N2730/10123

摘要： A method of treating chronic hepatitis B is disclosed that comprises administering a T cell-stimulating amount of a vaccine to a patient. The vaccine comprises an immunogenic amount of chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (core) protein (HBc) that is engineered for both enhanced stability of self-assembled particles and the substantial absence of nucleic acid binding by those particles. The chimeric protein molecule can include one or more immunogenic epitopes peptide-bonded to one or more of the N-terminus, the immunogenic loop or the C-terminus of HBc. The enhanced stability of self-assembled particles is obtained by the presence of at least one heterologous cysteine residue near one or both of the amino-terminus and carboxy-terminus of the chimer molecule.

公开(公告)号：EP1185663B1

公开(公告)日：2008-02-13

申请号：EP00935090.1

申请日：2000-05-22

申请人： ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A.

发明人： TRABONI, Cinzia, Istituto di Ricerche di Biologia

IPC分类号： C12N15/51 ,  C07K14/18 ,  C12Q1/68 ,  C12N7/00

CPC分类号： C07K14/005 ,  A61K2123/00 ,  C07K2319/00 ,  C12N2770/24222

摘要： Hitherto undiscovered 3' sequence of GBV confers infectivity in tamarins on otherwise non-infective GBV genome. HCV sequences may be substituted within an infective GBV genome to provide for in vivo assays for agents able to modulate HCV activity.

公开(公告)号：EP0585549B2

公开(公告)日：2008-01-09

申请号：EP93109289.4

申请日：1993-06-09

申请人： JAPAN as represented by Director General of Agency of NATIONAL INSTITUTE OF HEALTH

发明人： Miyamura, Tatsuo ,  Saito, Izumu ,  Matsuura, Yoshiharu ,  Honda, Yoshikazu ,  Seki, Makoto

IPC分类号： C07K14/18 ,  C12P21/02 ,  C12N5/06 ,  C12N15/51 ,  G01N33/48 ,  A61K39/29

CPC分类号： C07K14/005 ,  A61K39/00 ,  C12N2770/24222 ,  C12N2770/36122